Research Reports

Market Overview

• The Global 3D Printed Drugs Market is expected to grow at a CAGR of 19.20% during the forecasting period (2019-2026).
• 3D printed drugs are drugs manufactured by solidifying layers of materials to form a definite 3D structure. The adaptability of 3D printing is also applied for the precise and unique dosing of medicines, to present more efficient drug administration. 3D printing is expected to be an efficient method to enhance the application of several controlled drug release mechanisms, during the forecast period.
• The global 3D Printed Drugs market size was worth $ XX billion in 2018 and is estimated to reach $ XX billion by 2026, growing at a CAGR of XX% during the forecast period (2019-2026).

Download free sample: https://www.datamintelligence.com/download-sample/3d-printed-drugs-market

Market Dynamics

• The global 3D Printed Drugs market growth is driven by several factors such as, rising healthcare disorders globally and rising demand for cheaper drugs or pills, and increasing adaptability of 3D printing in the medical industries. With rising awareness towards to the advantages of 3D printed drugs, such as their instantaneous solubility. 3D printed drugs are extremely easy to swallow. As these drugs can be customized according to the requirement of every patient, assisting way better than batch-produced drugs, the demand is expected to grow over the forecast period.
• In addition, the increasing advancements in 3D printing technology and the rising investments to increase the research activities for the development of highly efficient 3D printed drugs are also expected to boost the growth of the market during the forecast period. For instance, in December 2017, Aprecia and Cycle Pharmaceuticals from Cambridge in the UK announced a partnership to develop and commercialise 3D printed tablets for orphan (rare) diseases using the ZipDose technology. In 2015, the Howard Hughes Medical Institute developed a molecular 3D printer for formulating new drugs by synthesizing blocks of small molecules from the basic chemical pattern.
• New players are also entering the market with advanced technology to meet the rising demand, which creates several opportunities in the market over the forecast period. For instance, FabRX, a biotech start-up that specializes in 3D printing medicines, is providing personalized medicines and drug-loaded medical devices through their patented technologies. The company’s propriety technology Printlets offers personalized dosages, polypills, chewable medicines, and fast-dissolving tablets. The company is also developing drug-loaded medical devices using SLA.
• However, the adverse effect of 3d printed drugs, lack of government regulations are expected to hinder the growth of the market.  Also, there are several scandals and hacking of data which is stored online which could results in patients being increasingly reluctant regarding disclosing their medical information. In addition, mislabelling of blueprints and inputting wrong description is also a big challenge for the market as a 3D blueprint is required to be made of the patient, their dosage, and medical history to prepare a 3D printed drug.

Market Segmentation

• By technology, the market is segmented into inkjet printing, fused deposition modelling (FDM), stereolithography (SLA), and others. The fused deposition modelling is expected to hold the highest market share during the forecast period, owing to the increasing innovations and technological advancement in the field of pharmaceutical drugs. Fused deposition modeling (FDM) is combined with hot melt extrusion (HME) to produce drug-loaded filaments, represents one promising technique for 3D printing drugs. However, the major challenge is that the temperatures needed during printing might degrade active pharmaceutical ingredients (APIs).
• On the other hand, the inkjet printer technology is estimated to grow at the highest growth rate over the forecast period, owing to high adoption among patients as it produces 3D Drugs tablets at a constant rate and has technologically advanced properties. In inkjet printing, different combinations of active ingredients and excipients (inks) are sprayed through a nozzle to deposit three-dimensional structures in solid dosage forms. This layer-by-layer deposition of the drug ingredient gives rise to a three-dimensional tablet.
• Stereolithography (SLA) is another promising technology for the fabrication of drug-loaded tablets. In general, SLA uses a laser beam to photopolymerize monomers. Using SLA, a team out of University College London combined a drug monomer with a photoinitiatior in order to produce a resin-based pill.
• By product, there is only one FDA approved 3D printed drug; however other drugs may enter into the market during the forecast period (20192-2026). In August 2015, the US Food and Drug Administration (FDA) approved the first three-dimensional printed oral drug product, Spritam (levetiracetam), from Aprecia Pharmaceuticals. Levetiracetam is indicated as adjunctive therapy for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and children with epilepsy. Spritam (levetiracetam) was developed with Aprecia's proprietary ZipDose technology, which uses three-dimensional printing to create a porous formulation of the antiepileptic that disintegrates rapidly with a sip of liquid, even at a high dose of up to 1000 mg.

Geographical Analysis

• North America is dominating the global 3D printed drugs market accounting for largest market share in 2018, owing to increasing number of chronic disorders, presence of advanced domestic healthcare infrastructure, high investment in research and development, and rising adoption of technological advancements in 3D printing. As Aprecia Pharmaceuticals has successfully got FDA approval of the first 3D printed drug, Spritam, and currently selling in the U.S market, hence, this region is the largest contributor to the market share of 3D printed drugs.

Competitive Landscape

• Aprecia Pharmaceuticals, FabRx Ltd. Technologies Inc., are the major players of 3D printed drugs market and GlaxoSmithKline (GSK) is considered to be a potential player as the organization is expecting to invest considerably in the industry over the forecast period (20129-2026). Other drug makers are expected to grab the market share in the near future on account of the swift advancements in technology.
• The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the 3D Printed Drugs market globally. For instance,
• In March 2019, Aprecia Pharmaceuticals and CMIC CMO collaborated to develop business opportunities in Japan for Aprecia’s ZipDose Technology and expand 3DP products globally. CMIC CMO’s services include identifying prospects in Japan, generating awareness and facilitating discussions of technology licensing agreements, research collaborations and distribution-partnerships. Through this engagement Aprecia seeks to expand its 3DP products globally, and this agreement highlights the importance of Japan in its long term strategy.
• In November 2018, Yissum, the technology transfer company of The Hebrew University announced a novel technology for the 3D printing of drug capsules. The technology is based on custom-printed 3D hydrogels with delayed release characteristics. This step help pave the way for pills that can be tailored to perform better than the conventional capsules manufactured currently.
• In December 2017, Aprecia Pharmaceuticals, a 3DP Pharmaceutical Company, and Cycle Pharmaceuticals Ltd. signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (3DP) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia's proprietary 3DP ZipDose Technology platform, which is the only three-dimensional printing technology for pharmaceutical drug product approved by the U.S. Food and Drug Administration

View full report: https://www.datamintelligence.com/research-report/3d-printed-drugs-market

Enquiry before buying: https://www.datamintelligence.com/enquiry/3d-printed-drugs-market

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com